Logos Global Management’s Ocular Therapeutix OCUL Stock Holding History

Logos Global Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52M	Buy	5,300,000 +1,450,000	+38%	+$13.1M	2.24%	16
2026 Q1	$32.6M	Buy	3,850,000 +350,000	+10%	+$3.34M	1.63%	20
2025 Q4	$42.5M	Buy	3,500,000 +250,000	+8%	+$3.04M	2.57%	9
2025 Q3	$38M	Buy	3,250,000 +1,050,000	+48%	+$12.6M	3.41%	6
2025 Q2	$20.4M	Sell	2,200,000 -100,000	-4%	-$783K	2.26%	14
2025 Q1	$16.9M	Sell	2,300,000 -1,200,000	-34%	-$9.22M	3%	14
2024 Q4	$29.9M	Hold	3,500,000	–	–	3.5%	10
2024 Q3	$30.4M	Sell	3,500,000 -1,650,000	-32%	-$13.6M	3.29%	10
2024 Q2	$35.2M	Sell	5,150,000 -661,436	-11%	-$4.08M	2.83%	10
2024 Q1	$52M	Buy	5,811,436 +1,811,436	+45%	+$12.9M	4.21%	6
2023 Q4	$17.8M	Buy	+4,000,000	New	+$11.8M	1.67%	19

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Logos Global Management's OCUL Position: Q2 2026 in Review

Logos Global Management increased its Ocular Therapeutix (OCUL) stake by 38% in Q2 2026, buying an estimated $13.1M and bringing the position to 5,300,000 shares worth $52M. The position accounts for 2.24% of the portfolio, ranked #16.

Logos Global Management first reported a position in OCUL in Q4 2023 and has held it in 11 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Logos Global Management held 5,300,000 shares of Ocular Therapeutix worth $52M as of Q2 2026.
Logos Global Management bought 1,450,000 Ocular Therapeutix shares in Q2 2026, an estimated $13.1M.
Ocular Therapeutix made up 2.24% of Logos Global Management's portfolio in Q2 2026, its #16 holding.
Logos Global Management first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 11 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.